X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Fanapt (iloperidone) is an atypical antipsychotic agent indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
Lead Product(s): Iloperidone
Therapeutic Area: Psychiatry/Psychology Product Name: Fanapt
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
Hetlioz (tasimelteon) is a melatonin receptor agonist. It is being evaluated in Phase 3 clinical trials for the treatment of insomnia characterized by difficulties with sleep initiation.
Lead Product(s): Tasimelteon
Therapeutic Area: Sleep Product Name: Hetlioz
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
VTR-297 (trichostatin A) is a small molecule histone deacetylase (HDAC) inhibitor with activity against dermatophytes and fungi. It is being evaluated in phase 2 clinical trials for the treatment of Onychomycosis.
Lead Product(s): Trichostatin A
Therapeutic Area: Infections and Infectious Diseases Product Name: VTR-297
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
VCA-894A (2'-O-methoxyethyl Phosphorothioate Oligonucleotide Sodium) specifically targets a cryptic splice site variant within immunoglobulin mu-binding protein 2 (IGHMBP2). It is being evaluated in preclinical studies for Charcot-Marie-Tooth Disease, Type 2S.
Lead Product(s): 2\'-O-methoxyethyl Phosphorothioate Oligonucleotide Sodium
Therapeutic Area: Genetic Disease Product Name: VCA-894A
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
Through the acquisition, Vanda expands its commercial portfolio by including Ponvory (ponesimod), a daily oral selective sphingosine-1-phosphate receptor 1 (S1P1R) modulator, indicated to treat adults with relapsing forms of multiple sclerosis.
Lead Product(s): Ponesimod
Therapeutic Area: Neurology Product Name: Ponvory
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Actelion Pharmaceuticals Ltd
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 07, 2023
Details:
VLY-686 (tradipitant) is an NK1R Inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of gastroparesis via oral capsule.
Lead Product(s): Tradipitant
Therapeutic Area: Gastroenterology Product Name: VLY-686
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
VCA-894A is a novel antisense oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S with a mechanism of action that specifically targets a cryptic splice site variant within immunoglobulin mu-binding protein 2 (IGHMBP2).
Lead Product(s): VCA-894A
Therapeutic Area: Genetic Disease Product Name: VCA-894A
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
VLY-686 (tradipitant) is a neurokinin-1 receptor antagonist licensed by Vanda from Eli Lilly and Company. Tradipitant is currently in clinical development for gastroparesis and motion sickness.
Lead Product(s): Tradipitant
Therapeutic Area: Neurology Product Name: VLY-686
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Fanapt® (iloperidone tablets), a novel atypical antipsychotic, in the treatment of acute manic and mixed episodes associated with bipolar I disorder in adults. Fanapt® is currently approved by the FDA for the treatment of schizophrenia in adults.
Lead Product(s): Iloperidone
Therapeutic Area: Psychiatry/Psychology Product Name: Fanapt
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
HETLIOZ® (tasimelteon), is a melatonin receptor agonist that is FDA approved for both Non-24-Hour Sleep-Wake Disorder (a serious, chronic circadian rhythm disorder) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older.
Lead Product(s): Tasimelteon
Therapeutic Area: Sleep Product Name: Hetlioz
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
